Limits...
Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus.

Ito H, Ishida H, Takeuchi Y, Antoku S, Abe M, Mifune M, Togane M - Nutr Metab (Lond) (2010)

Bottom Line: BMI did not change during the observation periods.The present study demonstrated the long-term beneficial effect of metformin in non-obese (BMI < 25 kg/m2) diabetic patients.This effect appears to be maintained even after the observation period of this study, because metformin was limited to a relatively low dose in the non-obese group and the observed worsening in glycemic control over time can probably be attenuated by increasing the dose of metformin.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, Tokyo 133-0052, Japan. ito@edogawa.or.jp.

ABSTRACT

Background: We aimed to investigate the long-term effect of metformin on the blood glucose control in non-obese patients with type 2 diabetes mellitus.

Methods: A retrospective study was performed in 213 patients with type 2 diabetes mellitus under the administration of metformin for more than one year. The clinical parameters were investigated for 3 years. The obese and non-obese individuals were defined as a body mass index (BMI) of 25 kg/m2 or over (n = 105) and a BMI of less than 25 kg/m2 (n = 108), respectively.

Results: HbA1c levels were significantly decreased compared with those at the baseline time. The course of HbA1c was similar between the non-obese and the obese groups, while the dose of metformin required to control blood glucose was significantly lower in the non-obese group than in the obese group. The reductions in HbA1c were 1.2% and 1.1% at 12 months, 0.9% and 0.9% at 24 months, and 0.8% and 1.0% at 36 months in the non-obese and obese groups, respectively. BMI did not change during the observation periods. Approximately half of all patients required no additional antidiabetic agents or a reduction in other treatments after the initiation of metformin in either of the two groups.

Conclusions: The present study demonstrated the long-term beneficial effect of metformin in non-obese (BMI < 25 kg/m2) diabetic patients. This effect appears to be maintained even after the observation period of this study, because metformin was limited to a relatively low dose in the non-obese group and the observed worsening in glycemic control over time can probably be attenuated by increasing the dose of metformin.

No MeSH data available.


Related in: MedlinePlus

Flow diagram of the population cohort. BMI: body mass index. OHAs: oral hypoglycemic agents.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2991324&req=5

Figure 1: Flow diagram of the population cohort. BMI: body mass index. OHAs: oral hypoglycemic agents.

Mentions: Three hundred ninety-five subjects who received metformin were conducted to be eligible for this study among 1371 patients with type 2 diabetes mellitus being treated in the Department of Diabetes, Metabolism and Kidney Diseases of Edogawa Hospital, Tokyo, Japan between April 2008 and March 2009 (Figure 1). Any individuals who had stopped visiting our department by changing the hospital or for other unspecified reasons for less than 1 year (n = 129) or who discontinued metformin within 1 year after the initiation because of side effects (n = 30), such as gastrointestinal symptoms and liver injury, were excluded from this study. The patients with an uncertain metformin treatment start date or without clinical characteristics at the baseline (before initiating metformin therapy) time were also excluded from the present series (n = 23). Finally, a retrospective study was performed in a population of 213 patients with type 2 diabetes mellitus under the consecutive administration of metformin for more than 1 year. The clinical parameters, including BMI, HbA1c level and the history of medication were investigated from the baseline (the initial date of metformin therapy) for 3 years.


Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus.

Ito H, Ishida H, Takeuchi Y, Antoku S, Abe M, Mifune M, Togane M - Nutr Metab (Lond) (2010)

Flow diagram of the population cohort. BMI: body mass index. OHAs: oral hypoglycemic agents.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2991324&req=5

Figure 1: Flow diagram of the population cohort. BMI: body mass index. OHAs: oral hypoglycemic agents.
Mentions: Three hundred ninety-five subjects who received metformin were conducted to be eligible for this study among 1371 patients with type 2 diabetes mellitus being treated in the Department of Diabetes, Metabolism and Kidney Diseases of Edogawa Hospital, Tokyo, Japan between April 2008 and March 2009 (Figure 1). Any individuals who had stopped visiting our department by changing the hospital or for other unspecified reasons for less than 1 year (n = 129) or who discontinued metformin within 1 year after the initiation because of side effects (n = 30), such as gastrointestinal symptoms and liver injury, were excluded from this study. The patients with an uncertain metformin treatment start date or without clinical characteristics at the baseline (before initiating metformin therapy) time were also excluded from the present series (n = 23). Finally, a retrospective study was performed in a population of 213 patients with type 2 diabetes mellitus under the consecutive administration of metformin for more than 1 year. The clinical parameters, including BMI, HbA1c level and the history of medication were investigated from the baseline (the initial date of metformin therapy) for 3 years.

Bottom Line: BMI did not change during the observation periods.The present study demonstrated the long-term beneficial effect of metformin in non-obese (BMI < 25 kg/m2) diabetic patients.This effect appears to be maintained even after the observation period of this study, because metformin was limited to a relatively low dose in the non-obese group and the observed worsening in glycemic control over time can probably be attenuated by increasing the dose of metformin.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, Tokyo 133-0052, Japan. ito@edogawa.or.jp.

ABSTRACT

Background: We aimed to investigate the long-term effect of metformin on the blood glucose control in non-obese patients with type 2 diabetes mellitus.

Methods: A retrospective study was performed in 213 patients with type 2 diabetes mellitus under the administration of metformin for more than one year. The clinical parameters were investigated for 3 years. The obese and non-obese individuals were defined as a body mass index (BMI) of 25 kg/m2 or over (n = 105) and a BMI of less than 25 kg/m2 (n = 108), respectively.

Results: HbA1c levels were significantly decreased compared with those at the baseline time. The course of HbA1c was similar between the non-obese and the obese groups, while the dose of metformin required to control blood glucose was significantly lower in the non-obese group than in the obese group. The reductions in HbA1c were 1.2% and 1.1% at 12 months, 0.9% and 0.9% at 24 months, and 0.8% and 1.0% at 36 months in the non-obese and obese groups, respectively. BMI did not change during the observation periods. Approximately half of all patients required no additional antidiabetic agents or a reduction in other treatments after the initiation of metformin in either of the two groups.

Conclusions: The present study demonstrated the long-term beneficial effect of metformin in non-obese (BMI < 25 kg/m2) diabetic patients. This effect appears to be maintained even after the observation period of this study, because metformin was limited to a relatively low dose in the non-obese group and the observed worsening in glycemic control over time can probably be attenuated by increasing the dose of metformin.

No MeSH data available.


Related in: MedlinePlus